Articles by Cynthia Challener, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Cynthia Challener, PhD

Reducing the Complexity of Commercial-Scale Amide Formation

Novel, atom-efficient routes to amides from esters and carboxylic acids for more sustainable manufacturing.
Jul 18, 2013

Novel, atom-efficient routes to amides from esters and carboxylic acids for more sustainable manufacturing.

New Cartridge Technology for High-Speed Filling in Parenteral Drug Manufacturing

New cartridges designed specifically for use on high-speed filling lines increase efficiency.
Jul 18, 2013

New cartridges designed specifically for use on high-speed filling lines increase efficiency.

Triple Quadrupole Mass Spectrometry Advances Pharmaceutical Analysis

For both small- and large-molecule applications, advances in mass spectrometry are leading to interest in this technique as an alternative to liquid chromatography.
Jul 18, 2013

For both small- and large-molecule applications, advances in mass spectrometry are leading to interest in this technique as an alternative to liquid chromatography.

Single-Use Continuous Chromatography Overcoming Limitations of Traditional Protein Purification

Continuous countercurrent tangential chromatography (CCTC) is a column-free process that provides a scalable, disposable, and cost-saving alternative to column chromatography.
Jul 18, 2013

Continuous countercurrent tangential chromatography (CCTC) is a column-free process that provides a scalable, disposable, and cost-saving alternative to column chromatography.

Strategies for Managing Surplus Assets in Pharmaceutical Manufacturing

Pharmaceutical industry restructuring has created different strategies for drug manufacturers to consider in managing surplus laboratory and manufacturing assets.
Jul 18, 2013

Pharmaceutical industry restructuring has created different strategies for drug manufacturers to consider in managing surplus laboratory and manufacturing assets.

Technology Choices in Highly Potent Solid Dosage Manufacturing

Risk management guides decisions in facility design and operation for highly potent drugs.
Jul 2, 2013

Risk management guides decisions in facility design and operation for highly potent drugs.

GE Healthcare, iBio, and Bio-Manguinhos/Fiocruz Advance Large-Scale Plant-Based Protein Production

GE Healthcare's partnerships with iBio and Brazil's Bio-Manguinhos/Fiocruz for a new plant-based multipurpose biopharmaceutical and vaccine manufacturing facility move plant-based protein production to the next level.
Jul 2, 2013

GE Healthcare's partnerships with iBio and Brazil's Bio-Manguinhos/Fiocruz for a new plant-based multipurpose biopharmaceutical and vaccine manufacturing facility move plant-based protein production to the next level.

New Chiral Sulfur and Phosphorous Chemistry from Boehringer Ingelheim

New routes enable the efficient synthesis of enantiopure sulfinamides and structurally and sterically diverse P-chiral phosphine oxides.
Jul 2, 2013

New routes enable the efficient synthesis of enantiopure sulfinamides and structurally and sterically diverse P-chiral phosphine oxides.

Addressing Manufacturing Challenges with Nondestructive X-Ray Imaging

Greater sophistication in 3D X-ray imaging technology raises its utility for QA/QC in manufacturing.
Jul 2, 2013

Greater sophistication in 3D X-ray imaging technology raises its utility for QA/QC in manufacturing.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here